Sirnaomics Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US Premium The company is also pushing ahead with a microRNA-replacement therapy that is designed to improve patient response to colon cancer treatment. Sirnaomics Presents Preclinical HPV Data Premium Sirnaomics this week released preclinical data showing that two siRNAs against different strains of human papillomavirus could halt growth of papillomas in an animal model of HPV infection. Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field Premium Sirnaomics could begin phase I testing of its siRNA-based wound-healing drug candidate STP-705 as soon as next year and expects to run the trial in China, a company official told Gene Silencing News this week. Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker Premium The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets. Sirnaomics Partners with Chinese Pharma on Wound-Healing Drug Premium The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said. Jul 8, 2010 NIH Awards Three Grants Supporting RNAi, microRNA Rx Development Premium Jun 24, 2010 Sirnaomics Aims to Move Wound-Healing Drug into Phase I Next Year Premium Jun 17, 2010 Choosing Skin and Eye Disorders, RXi Will Face Well-Worn R&D Paths Premium Jan 14, 2010 Sirnaomics Licenses Polypeptide Nanoparticle Delivery Technology from University of Maryland Medical School Premium Jul 23, 2009 Sirnaomics Receives NCI Grant to Develop siRNA-Based Lung Cancer Rx Premium Feb 24, 2009 Sirnaomics Considers Hong Kong for Ocular Rx Trial Premium Feb 5, 2009 Sirnaomics Considers Hong Kong for Ocular Disease Rx Trial, Advances Wound-Healing Program Premium Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.